在线办公
期刊论坛
主 管
中国人民解放军总医院
主 办
中国人民解放军总医院老年心血管病研究所
中国科技出版传媒股份有限公司
编 辑
中华老年多器官疾病杂志编辑委员会
100853, 北京市复兴路28号
电话:010-66936756
传真:010-66936756
E-mail: zhlndqg@mode301.cn
创刊人 王士雯
总编辑 范利
副总编辑 陈韵岱
执行主编 叶大训
编辑部主任 王雪萍
ISSN 1671-5403
CN 11-4786
创刊时间 2002年
出版周期 月刊
邮发代号 82-408
友情链接
张骞,吕凌燕,扈桂海,侯学全,刘士茂.阿仑膦酸钠治疗老年糖尿病合并骨质疏松的临床效果[J].中华老年多器官疾病杂志,2019,18(11):860~863
阿仑膦酸钠治疗老年糖尿病合并骨质疏松的临床效果
Clinical efficacy of alendronate in treatment of elderly diabetic patients complicated with osteoporosis
投稿时间:2019-06-24  
DOI:10.11915/j.issn.1671-5403.2019.11.179
中文关键词:  老年人;阿仑膦酸钠;糖尿病;骨质疏松
英文关键词:aged; alendronate sodium; diabetes mellitus; osteoporosis Corresponding author:ZHANG Qian, E-mail:inwsuwk@163.com〖FL
基金项目:
作者单位E-mail
张骞 山东省聊城市第二人民医院脊柱外科,聊城 252601 inwsuwk@163.comclinical 
吕凌燕 山东省聊城市第二人民医院脊柱外科,聊城 252601 inwsuwk@163.comclinical 
扈桂海 山东省聊城市第二人民医院脊柱外科,聊城 252601 inwsuwk@163.comclinical 
侯学全 山东省聊城市第二人民医院脊柱外科,聊城 252601 inwsuwk@163.comclinical 
刘士茂 山东省聊城市第二人民医院脊柱外科,聊城 252601 inwsuwk@163.comclinical 
摘要点击次数: 46
全文下载次数: 45
中文摘要:
      目的 观察阿仑膦酸钠治疗老年糖尿病合并骨质疏松的临床效果。方法 选取2017年6月至2018年12月期间我院收治的100例糖尿病合并骨质疏松的老年患者作为研究对象,根据入院的奇偶顺序分别纳入对照组和治疗组,各50例。对照组给予常规方法治疗,治疗组在对照组的基础上给予口服阿仑膦酸钠治疗。两组均治疗3个月。比较2组患者治疗前后骨代谢标志物Ⅰ型胶原交联氨基端肽(NTXI)、Ⅰ型胶原交联羧基端肽(CTXI)、抗酒石酸酸性磷酸酶5b(TRACP5b)和血骨钙素(BGP)、骨密度(BMD)和骨碱性磷酸酶(BALP)等,并比较2组患者临床治疗效果。采用SPSS 18.0软件对数据进行统计学分析。结果 治疗组的总有效率明显高于对照组,差异具有统计学意义(92.0%和64.0%, P<0.05)。治疗前两组患者的NTXI、CTXI、TRACP5b、BGP、BMD和BALP等水平差异均无统计学意义(P>0.05)。治疗后,2组NTXI、CTXI、TRACP5b、BGP和BALP水平均显著低于治疗前,且治疗组显著低于对照组[NTXI:(32.22±5.45)和(43.02±5.74)nmol/L;CTXI:(178.36±16.43)和(208.34±19.22)ng/L;TRACP5b:(3.10±0.81)和(3.86±0.85)ng/L; BGP:(2.16±0.46)和(5.44±1.37)μg/L及BALP:(237.33±18.28)和(270.43±21.12)U/L],差异均有统计学意义(P<0.01)。治疗后,2组BMD均显著高于治疗前,且治疗组显著高于对照组[(0.97±0.17)和(0.82±0.13)g/cm2],差异具有统计学意义(P<0.01)。结论 阿仑膦酸钠治疗老年糖尿病合并骨质疏松的临床效果显著,值得临床推广。
英文摘要:
      Objective To observe the clinical effect of alendronate sodium in the treatment of senile diabetes mellitus complicated with osteoporosis. Methods A total of 100 elderly diabetes mellitus patients complicated with senile osteoporosis admitted in our hospital from June 2017 to December 2018 were recruited in this study, and according to the parity order of their hospitalized admision, they were assigned into control group and treatment group, with 50 cases in each group. The control group were given conventional treatment, and the treatment group were given same treatment and oral administration of alendronate sodium phosphonic acid for 3 months. Bone metabolism markers, type Ⅰ collagen cross-linked aminoterminus peptide (NTXI), type Ⅰ collagen cross-linked carboxyl terminus peptide (CTXI), anti-tartaric acid phosphatase 5b (TRACP5b), blood osteocalcin (BGP), and bone alkaline phosphatase (BALP) and bone mineral density (BMD) were detected in the 2 groups before and after treatment to compare the clinical treatment effect. SPSS statistics 18.0 was used for data analysis. Results The overall response rate was significantly higher in the treatment group than in the control group (92.0% vs 64.0%, P<0.05). There were no significant differences in NTXI, CTXI, TRACP5b, BGP, BMD and BALP between the 2 groups before treatment (P>0.05), and the levels were significantly decreased after the treatment, with those in the treatment group lower than those of the control group [(NTXI:(32.22±5.45) vs (43.02±5.74)nmol/L, CTXI:(178.36±16.43) vs (208.34±19.22)ng/L, TRACP5b:(3.10±0.81) vs (3.86±0.85)ng/L, BGP:(2.16±0.46) vs (5.44±1.37)μg/L, BALP:(237.33±18.28) vs (270.43±21.12)U/L, all P<0.01]. The BMD was increased in both group, and that in the treatment group [(0.97±0.17)g/cm2] was significantly higher than that of the control group [(0.82±0.13)g/cm2, P<0.01]. Conclusion Alendronate sodium is of significant efficacy in the treatment of senile diabetes mellitus combined with osteoporosis, and is worthy of clinical promotion.
查看全文    下载PDF阅读器
关闭